aTYR PHARMA (ATYR) Cash & Current Investments (2014 - 2026)

aTYR PHARMA (ATYR) has reported Cash & Current Investments for 13 consecutive years, with $57.4 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Cash & Current Investments fell 28.54% year-over-year to $57.4 million; the trailing twelve-month figure through Jun 2026 stood at $57.4 million (down 28.54% YoY), and the FY2025 full-year result was $78.7 million, up 9.1% from the prior year.
• Cash & Current Investments declined to $57.4 million in Q2 2026 per ATYR's latest filing, from $66.5 million in the prior quarter.
• Across five years, Cash & Current Investments topped out at $114.4 million in Q1 2023 and bottomed at $57.4 million in Q2 2026.
• Historically, Cash & Current Investments has averaged $83.6 million across 5 years, with a median of $79.5 million in 2025.
• The widest YoY moves for Cash & Current Investments: up 100.98% in 2022, down 38.7% in 2022.
• Over 5 years, Cash & Current Investments stood at $66.1 million in 2022, then soared by 48.41% to $98.2 million in 2023, then declined by 26.53% to $72.1 million in 2024, then grew by 9.1% to $78.7 million in 2025, then slipped by 27.03% to $57.4 million in 2026.
• According to Business Quant data, Cash & Current Investments over the past three periods registered $57.4 million, $66.5 million, and $78.7 million for Q2 2026, Q1 2026, and Q4 2025 respectively.